Literature DB >> 2807151

Medullary thyroid carcinoma: prognosis of familial versus nonfamilial disease and the role of radiotherapy.

N A Samaan1, P N Schultz, R C Hickey.   

Abstract

A retrospective study of 202 patients with medullary thyroid carcinoma (MTC) diagnosed between 1943 and 1987 was done to compare the prognosis of patients with sporadic disease and those with the familial form of multiple endocrine neoplasia type II (MEN-II) and to study the effect of radiotherapy. The relationship between serum calcitonin (iCT), carcinoembryonic antigen (CEA), and calcitonin gene-related peptide (CGRP) to the extent of disease and prognosis was also studied. Patients with MEN-II had significantly longer survival rates than did patients with the sporadic variety (P less than 0.005), but most patients with sporadic disease were older and had more advanced disease. No differences in survival rates were found when patients from these two groups were matched for age and extent of disease (P greater than 0.7). When patients who received radiotherapy were matched for age, extent of disease, and surgery with patients who had had no radiotherapy, the latter group was found to live significantly longer (P less than 0.05). Our studies suggested (1) that the apparently poor prognosis of patients with sporadic MTC may be related to the patients' older age at detection rather than to inherent differences in the two forms of disease, (2) radiotherapy has little effect on MTC, (3) calcitonin gene-related peptide measurement was not helpful in determining the extent of disease or prognosis, (4) patients with liver metastasis had the highest iCT levels, (5) patients with bone metastasis had the highest CEA levels, and (6) patients with diarrhea had poor prognosis and had high iCT levels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2807151

Source DB:  PubMed          Journal:  Horm Metab Res Suppl        ISSN: 0170-5903


  8 in total

1.  Nuclear DNA content of medullary thyroid carcinoma in a large family with the MEN-2A syndrome.

Authors:  H R Haak; C J Cornelisse; B M Goslings; G J Fleuren
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

2.  Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection.

Authors:  J F Moley; M K DeBenedetti
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

3.  Markov model-based estimation of individual survival probability for medullary thyroid cancer patients.

Authors:  Olga Esik; Gábor Tusnády; Lajos Trón; András Boér; Zoltán Szentirmay; István Szabolcs; Károly Rácz; Erzsébet Lengyel; Judit Székely; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

4.  Thyroid neoplasm after central nervous system irradiation for medulloblastoma in childhood: report of two cases.

Authors:  Benedetta Ludovica Pettorini; Alessandro Narducci; Antonella de Carlo; Francesca Abet; Massimo Caldarelli; Luca Massimi; Gianpiero Tamburrini; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2009-02-19       Impact factor: 1.475

5.  The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.

Authors:  Mohsen Beheshti; Sigrid Pöcher; Reza Vali; Peter Waldenberger; Gabriele Broinger; Michael Nader; Susanne Kohlfürst; Christian Pirich; Henning Dralle; Werner Langsteger
Journal:  Eur Radiol       Date:  2009-01-21       Impact factor: 5.315

Review 6.  Medullary thyroid cancer: medical management and follow-up.

Authors:  Amber Traugott; Jeffrey F Moley
Journal:  Curr Treat Options Oncol       Date:  2005-07

7.  Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery.

Authors:  Matthias Schott; Holger S Willenberg; Cornelia Sagert; Thi-Bang-Tam Nguyen; Sven Schinner; Mathias Cohnen; Kenko Cupisti; Claus F Eisenberger; Wolfram T Knoefel; Werner A Scherbaum
Journal:  Clin Endocrinol (Oxf)       Date:  2007-03       Impact factor: 3.478

8.  Medullary thyroid carcinoma.

Authors:  Jeffrey F Moley
Journal:  Curr Treat Options Oncol       Date:  2003-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.